Monitoring Cell-surfaceN-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation.
The plasma membrane proteome plays a crucial role in inter- and intracellular signaling, cell survival, and cell identity. As such, it is a prominent target for pharmacological intervention. The relatively low abundance of this subproteome in conjunction with challenging extractability and solubility still hampers its comprehensive analysis. Here, we combined a chemical glycoprotein-tagging strategy with mass spectrometry to enable comprehensive analysis of the cell-surface glycoproteome. To benchmark this workflow and to provide guidance for cell line selection for functional experiments, we generated an inventory of theN-linked cell-surface glycoproteomes of 15 standard laboratory human cell lines and three primary lymphocytic cell types. On average, about 900 plasma membrane and secreted proteins were identified per experiment, including more than 300 transporters and ion channels. Primary cells displayed distinct expression of surface markers and transporters underpinning the importance of carefully validating model cell lines selected for the study of cell surface-mediated processes. To monitor dynamic changes of the cell-surface proteome in a highly multiplexed experiment, we employed an isobaric mass tag-based chemical labeling strategy. This enabled the time-resolved analysis of plasma membrane protein presentation during differentiation of the monocytic suspension cell line THP-1 into macrophage-like adherent cells. Time-dependent changes observed in membrane protein presentation reflect functional remodeling during the phenotypic transition in three distinct phases: rapid surface presentation and secretion of proteins from intracellular pools concurrent with rapid internalization of no longer needed proteins and finally delayed presentation of newly synthesized macrophage markers. Perturbation of this process using marketed receptor tyrosine kinase inhibitors revealed dasatinib to severely compromise macrophage differentiation due to an off-target activity. This finding suggests that dynamic processes can be highly vulnerable to drug treatment and should be monitored more rigorously to identify adverse drug effects.
From ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Mathias
M
Kalxdorf
From ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Stephan
S
Gade
From ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany hans-christian.h.eberl@gsk.com marcus.x.bantscheff@gsk.com.
H Christian
HC
Eberl
From ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany hans-christian.h.eberl@gsk.com marcus.x.bantscheff@gsk.com.
Marcus
0000-0002-8343-8977
M
Bantscheff
D019921:Biotinylation; D002454:Cell Differentiation; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism*; D000069439:Dasatinib / Q000494:pharmacology; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D008264:Macrophages / Q000166:cytology* / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism*; D009000:Monocytes / Q000166:cytology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results
D006023:Glycoproteins; D008565:Membrane Proteins; D047428:Protein Kinase Inhibitors; D020543:Proteome; D000069439:Dasatinib